Mi SciELO
Servicios personalizadosServicios Personalizados
Revista
Articulo
Inglés (pdf)
Articulo en XML
Referencias del artículo
Traducción automática
Enviar articulo por emailIndicadores
Citado por SciELO 
Accesos
Links relacionados
Citado por Google 
Similares en
SciELO 
Similares en Google
Compartir
Permalink
Revista de la OFIL
versión On-line ISSN 1699-714Xversión impresa ISSN 1131-9429
Resumen
MORENO-RAMOS, C; GIL-SIERRA, MD; BRICENO-CASADO, MP y RIOS-SANCHEZ, E. Influence of first-line anti-TNF therapy on the effectiveness of adalimumab in ulcerative colitis: long-term clinical practice data. Rev. OFIL·ILAPHAR [online]. 2024, vol.34, n.2, pp.131-134. Epub 28-Mar-2025. ISSN 1699-714X. https://dx.doi.org/10.4321/s1699-714x2024000200007.
Objetive:
Tumour necrosis factor (TNF) is a relevant therapeutic target in the treatment of inflammatory diseases. The objective was to determine the influence of the effect of a first-line anti-TNF regimen on the effectiveness of adalimumab, as well as to obtain real long-term data.
Methods:
Retrospective descriptive study was conducted between January 2013 and July 2021. Patients diagnosed with ulcerative colitis treated with adalimumab who previously received at least one anti-TNF agent were included. Mayo Clinic Score up to 72 months was measured as effectiveness endpoint.
Results:
Thirty-one patients were included. More than a third of patients treated with adalimumab as second-line anti-TNF had primary non-response. More than half of the patients treated with adalimumab presented clinical remission or response at 6 months of treatment, decreasing to one-tenth at 72 months.
Conclusion:
The use of two anti-TNF therapy could be a strategy with acceptable effectiveness and favorable efficiency.
Palabras clave : Ulcerative colitis; tumour necrosis factor inhibitors; adalimumab; treatment failure; long term effect.
